Skip to content
Subscriber Only

China Secures 100 Million Doses of BioNTech Vaccine

  • BioNTech to supply vaccines to Fosun as part of marketing pact
  • Imported vaccines needed despite massive domestic production
The Pfizer-BioNTech Covid-19 vaccine.

The Pfizer-BioNTech Covid-19 vaccine.

Photographer: Bing Guan/Bloomberg
Updated on

A Chinese drugmaker has secured 100 million doses of the coronavirus vaccine co-developed by Pfizer Inc. and BioNTech SE, as the country seeks overseas shots in addition to home-made ones to ensure immunization for the world’s most populous nation.

Shanghai Fosun Pharmaceutical Group Co., which in March made an agreement with BioNTech to develop and market the mRNA shot in China, will make an advance payment of 250 million euros ($300 million) for an initial 50 million doses. The German vaccine maker will supply no fewer than 100 million doses for China by the end of 2021, Fosun said in a statement filed with the Hong Kong Stock Exchange Wednesday.